TY - JOUR
T1 - Corona Immunitas
T2 - study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland
AU - the Corona Immunitas Research Group
AU - West, Erin A.
AU - Anker, Daniela
AU - Amati, Rebecca
AU - Richard, Aude
AU - Wisniak, Ania
AU - Butty, Audrey
AU - Albanese, Emiliano
AU - Bochud, Murielle
AU - Chiolero, Arnaud
AU - Crivelli, Luca
AU - Cullati, Stéphane
AU - d’Acremont, Valérie
AU - Epure, Adina Mihaela
AU - Fehr, Jan
AU - Flahault, Antoine
AU - Fornerod, Luc
AU - Frank, Irène
AU - Frei, Anja
AU - Michel, Gisela
AU - Gonseth, Semira
AU - Guessous, Idris
AU - Imboden, Medea
AU - Kahlert, Christian R.
AU - Kaufmann, Laurent
AU - Kohler, Philipp
AU - Mösli, Nicolai
AU - Paris, Daniel
AU - Probst-Hensch, Nicole
AU - Rodondi, Nicolas
AU - Stringhini, Silvia
AU - Vermes, Thomas
AU - Vollrath, Fabian
AU - Puhan, Milo A.
AU - Amendola, Antonio
AU - Annoni, Anna Maria
AU - Azman, Andrew
AU - Bally, Frank
AU - Balmer, Bettina
AU - Baysson, Hélène
AU - Berthod, Delphine
AU - Blankenberger, Jacob
AU - Bodenmann, Patrick
AU - Bopp, Matthias
AU - Camerini, Anne Linda
AU - Cappeli, Céline
AU - Carmelli, Cristian
AU - Collombet, Prune
AU - Corna, Laurie
AU - Crawford, Jenny
AU - Cusini, Alexia
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - Objectives: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. Methods: Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic. Results: Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far. Conclusions: Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860.
AB - Objectives: Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community. Methods: Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic. Results: Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2–13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far. Conclusions: Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860.
KW - Hygiene practices
KW - Longitudinal
KW - Prevalence
KW - SARS-CoV-2
KW - Serosurvey
KW - Socioeconomic differences
UR - http://www.scopus.com/inward/record.url?scp=85092544805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092544805&partnerID=8YFLogxK
U2 - 10.1007/s00038-020-01494-0
DO - 10.1007/s00038-020-01494-0
M3 - Article
C2 - 33098441
AN - SCOPUS:85092544805
SN - 1661-8556
VL - 65
SP - 1529
EP - 1548
JO - International Journal of Public Health
JF - International Journal of Public Health
IS - 9
ER -